SONN Sonnet BioTherapeutics Holdings, Inc.

SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.

$0.28
As of 06/24/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/04/2019
Outstanding shares:  60,587,905
Average volume:  2,875,753
Market cap:   $16,698,027
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.79
PB ratio:   1.97
PS ratio:   23.56
Return on equity:   -322.00%
Net income %:   -3,876.87%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy